Sales of Eleven Systems to Norway and China

Report this content

C-RAD received orders for two Catalysts and one Sentinel from a clinic in Norway. The Chinese distributor ordered a package of three Catalyst and five laser systems.

 

The hospital in Kristiansand decided for the fully equipped Catalyst System including Respiratory Gating and also the modules for Patient Positioning and Motion Monitoring. The installation will take place beginning of 2014. Kristiansand is a cooperation partner to Oslo University Hospital. The entire group includes also the radiotherapy center in Gjøvik, Ullevål, Rikshospitalet with all together more than 20 linear accelerators.

 

The systems to the Chinese market will be installed in different radiotherapy centers in the larger area of Beijing and Shanghai. The major part will be delivered before the end of this year. The installations are expected within the first half of 2014.

 

Tim Thurn, CEO, C-RAD AB:

“I am very satisfied with the two large orders. It was a successful start with our new cooperation partner in China. We see a strong interest among the customers for the C-RAD products but also for the new laser systems. Kristiansand will be the second installation in Norway where patients and personnel can enjoy the benefits of C-RAD technology. Other radiotherapy centers in the group showed already interest in C-RAD products. The first three quarters developed successfully for C-RAD. We expect the same development in the last quarter.”

 

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 29 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian  and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.

For more information on C-RAD, please visit www.c-rad.com.

 

 

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com